Citation Impact
Citing Papers
Role of UEV-1, an Inactive Variant of the E2 UbiquitinConjugating Enzymes, in In Vitro Differentiation and Cell Cycle Behavior of HT-29-M6 Intestinal Mucosecretory Cells
1998 StandoutNobel
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
2004 StandoutScience
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
2010
Telomeric Protein Pin2/TRF1 as an Important ATM Target in Response to Double Strand DNA Breaks
2001
Hallmarks of Cancer: The Next Generation
2011 Standout
A large-scale RNAi screen in human cells identifies new components of the p53 pathway
2004
Mutations of mitotic checkpoint genes in human cancers
1998 Nature
Cellular and Gene Expression Responses Involved in the Rapid Growth Inhibition of Human Cancer Cells by RNA Interference-mediated Depletion of Telomerase RNA
2005 StandoutNobel
Improved methods for the generation of human gene knockout and knockin cell lines
2005
Role for the p53 homologue p73 in E2F-1-induced apoptosis
2000 StandoutNatureNobel
TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
2006 Standout
Apoptosis in cancer
2000 Standout
The β-Catenin/TCF-4 Complex Imposes a Crypt Progenitor Phenotype on Colorectal Cancer Cells
2002 Standout
Influence of Metabolism on Epigenetics and Disease
2013 StandoutNobel
Multiple pathways control cell growth and transformation: overlapping and independent activities of p53 and p21Cip1/WAF1/Sdi1
1997
Evolution of the cancer genome
2012
p53, the Cellular Gatekeeper for Growth and Division
1997 Standout
p53 Inhibits Hypoxia-inducible Factor-stimulated Transcription
1998
Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors
2006 StandoutNobel
Genetic knockouts and knockins in human somatic cells
2007
Elite and stochastic models for induced pluripotent stem cell generation
2009 StandoutNatureNobel
Genetic instabilities in human cancers
1998 StandoutNature
Mutant PIK3CA promotes cell growth and invasion of human cancer cells
2005
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
1998 StandoutNatureNobel
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
2012 StandoutNatureNobel
PI3K pathway alterations in cancer: variations on a theme
2008
Genetic analysis of chemoresistance in primary murine lymphomas
2000
When Checkpoints Fail
1997 StandoutNobel
The spindle assembly checkpoint
1996
HIF-1α Induces Genetic Instability by Transcriptionally Downregulating MutSα Expression
2005 StandoutNobel
Degradation of Cdc25A by β-TrCP during S phase and in response to DNA damage
2003 StandoutNatureNobel
The Hallmarks of Cancer
2000 Standout
Telomere Shortening Triggers Senescence of Human Cells through a Pathway Involving ATM, p53, and p21CIP1, but Not p16INK4a
2004
A stress response pathway regulates DNA damage through β2-adrenoreceptors and β-arrestin-1
2011 StandoutNatureNobel
INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53
1999
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
2010 Standout
Phosphorylation by Casein Kinase I Promotes the Turnover of the Mdm2 Oncoprotein via the SCFβ-TRCP Ubiquitin Ligase
2010 StandoutNobel
KLF4, p21 and context-dependent opposing forces in cancer
2005
Nucleotide Excision Repair in Mammalian Cells
1997
HIF‐1α induces cell cycle arrest by functionally counteracting Myc
2004
Inhibiting the p53–MDM2 interaction: an important target for cancer therapy
2003
The role of apoptosis in cancer development and treatment response
2005
Transgenic mouse model for studying the transcriptional activity of the p53 protein: age- and tissue-dependent changes in radiation-induced activation during embryogenesis
1997
14-3-3σ is required to prevent mitotic catastrophe after DNA damage
1999 Nature
Expression of mutant telomerase in immortal telomerase-negative human cells results in cell cycle deregulation, nuclear and chromosomal abnormalities and rapid loss of viability
2001
Foundations in Cancer Research p53 and ATM: Cell Cycle, Cell Death, and Cancer
1997
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage
1999 StandoutNatureNobel
Apoptosis
2002 Standout
Overexpression of E2F‐1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo
1998
The DNA damage response and cancer therapy
2012 Nature
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage
2000 Nature
p73 is a human p53-related protein that can induce apoptosis
1997 StandoutNatureNobel
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
2010
p53 Deficiency Rescues the Adverse Effects of Telomere Loss and Cooperates with Telomere Dysfunction to Accelerate Carcinogenesis
1999 StandoutNobel
Ferredoxin reductase affects p53-dependent, 5-fluorouracil–induced apoptosis in colorectal cancer cells
2001
A model for p53-induced apoptosis
1997 StandoutNature
Causes and consequences of aneuploidy in cancer
2012
Clinical implications of p53 mutations
1999
The DNA damage response: putting checkpoints in perspective
2000 StandoutNature
Revealing the world of RNA interference
2004 StandoutNatureNobel
The Shortest Telomere, Not Average Telomere Length, Is Critical for Cell Viability and Chromosome Stability
2001 StandoutNobel
p53 regulation by post-translational modification and nuclear retention in response to diverse stresses
1999
5-Fluorouracil: mechanisms of action and clinical strategies
2003 Standout
AAV-mediated gene targeting methods for human cells
2011
CDC5 and CKII Control Adaptation to the Yeast DNA Damage Checkpoint
1997 StandoutNobel
A common E2F-1 and p73 pathway mediates cell death induced by TCR activation
2000 StandoutNatureNobel
Ras, PI(3)K and mTOR signalling controls tumour cell growth
2006 StandoutNature
Myc suppression of the p21Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage
2002 Nature
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
2010 Standout
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
2012 Nature
2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP+-Dependent Isocitrate Dehydrogenase Mutations
2011
Transcriptional Repression of the Anti-apoptoticsurvivin Gene by Wild Type p53
2002
DNA Damage-Induced Activation of p53 by the Checkpoint Kinase Chk2
2000 Science
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α
2000 StandoutNobel
Genetic instability and darwinian selection in tumours
1999
Chk1 is an essential kinase that is regulated by Atr and required for the G2/M DNA damage checkpoint
2000
Human Rif1 protein binds aberrant telomeres and aligns along anaphase midzone microtubules
2004 StandoutNobel
Genetic instability and darwinian selection in tumours
1999
The G2-phase DNA-damage checkpoint
2000
GADD45 induction of a G 2 /M cell cycle checkpoint
1999
Quality Control by DNA Repair
1999 StandoutScienceNobel
Cancer Cell Cycles
1996 StandoutScience
Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas
2012
p53-dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells
1998
Role of BAX in the Apoptotic Response to Anticancer Agents
2000 Science
Heterozygous Germ Line hCHK2 Mutations in Li-Fraumeni Syndrome
1999 Science
Use and Abuse of RNAi to Study Mammalian Gene Function
2012 StandoutScienceNobel
c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo.
2001
High rate of CAD gene amplification in human cells deficient in MLH1 or MSH6
2001 StandoutNobel
Human DNA Repair Genes
2001 StandoutScienceNobel
The N-Terminal Domain of p73 Interacts with the CH1 Domain of p300/CREB Binding Protein and Mediates Transcriptional Activation and Apoptosis
2000
Integrating Genetic Approaches into the Discovery of Anticancer Drugs
1997 StandoutScienceNobel
hMutSα- and hMutLα-dependent phosphorylation of p53 in response to DNA methylator damage
1999 StandoutNobel
The human Rad9–Rad1–Hus1 checkpoint complex stimulates flap endonuclease 1
2004 StandoutNobel
The Human ARF Cell Cycle Regulatory Gene Promoter Is a CpG Island Which Can Be Silenced by DNA Methylation and Down-Regulated by Wild-Type p53
1998
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
2009 StandoutScience
p53-mediated apoptosis requires inositol hexakisphosphate kinase-2
2010
Cell Cycle Checkpoints: Preventing an Identity Crisis
1996 StandoutScience
Apoptosis, p53, and tumor cell sensitivity to anticancer agents.
1999
Another p53 Doppelgänger?
1998 StandoutScienceNobel
Spectral karyotyping suggests additional subsets of colorectal cancers characterized by pattern of chromosome rearrangement
2001
Works of Todd Waldman being referenced
Identification of p18INK4c as a Tumor Suppressor Gene in Glioblastoma Multiforme
2008
Mutational Inactivation of STAG2 Causes Aneuploidy in Human Cancer
2011 Science
IDH1 mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain
2010
Cell-cycle arrest versus cell death in cancer therapy
1997
Epitope tagging of endogenous genes in diverse human cell lines
2008
Disruption of p53 in human cancer cells alters the responses to therapeutic agents
1999
Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21
1996 Nature
p53 tagged sites from human genomic DNA
1994
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
2009
Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues.
1995
p21 is necessary for the p53-mediated G1 arrest in human cancer cells.
1995
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
1998 StandoutScience
Oncogenic beta-catenin is required for bone morphogenetic protein 4 expression in human cancer cells.
2002
PTENGene Targeting Reveals a Radiation-Induced Size Checkpoint in Human Cancer Cells
2004
Genetic determinants of p53-induced apoptosis and growth arrest.
1996
Activation of p53-Dependent Growth Suppression in Human Cells by Mutations in PTEN or PIK3CA
2006
Repair Defect in p21 WAF1/CIP1 -/- human cancer cells.
1996